CELZ — Creative Medical Technology Holdings Share News
0.000.00%
Last trade - 00:00- $4.88m
- -$3.81m
- $0.01m
Brief: Creative Medical Technology Holdings Successfully Completes Enrollment And Treatment Across Entire FDA-Cleared Adapt Trial, Including Opioid Cohort, Advancing Celz-201 / Olastrocel Toward Rmat Evaluation And Phase 3 Planning
Creative Medical Technology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
NASDAQ RESUMED AT 11:07 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:02 AM
NASDAQ RESUMED AT 11:01 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:56 AM
NASDAQ RESUMED AT 10:55 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:50 AM
Creative Medical Technology Holdings Inc expected to post a loss of 39 cents a share - Earnings Preview
NASDAQ RESUMED AT 09:40 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:35 AM
Brief: Creative Medical Technology Holdings Achieves Second Who Inn Milestone
Brief: Creative Medical Technology Holdings Reaches Major Clinical Inflection Point With Positive Interim Data From Adapt Trial And Celz-201 (Olastrocel) In The Treatment Of Chronic Lower Back Pain
Brief: Creative Medical Technology Receives Approval For Biodefense Burn Pit Initiative
Brief: Creative Medical Technology Completes Enrollment In FDA-Cleared Adapt Trial
Brief: Creative Medical Technology Holdings Announces World Health Organization Approval Of “Olastrocel”
Brief: Creative Medical Technology Holdings Announces Agreements For Exercise Of Warrants For $4.2 Million Gross Proceeds
Creative Medical Technology Holdings Inc expected to post a loss of 63 cents a share - Earnings Preview
Creative Medical Technology Holdings Inc expected to post a loss of 40 cents a share - Earnings Preview